Methyl BioActive Australia - English - Department of Health (Therapeutic Goods Administration)

methyl bioactive

fit-bioceuticals pty ltd - pyridoxal 5-phosphate monohydrate, quantity: 51.09 mg (equivalent: pyridoxine, qty 32.6 mg); riboflavin sodium phosphate, quantity: 32.89 mg (equivalent: riboflavin, qty 25 mg); mecobalamin, quantity: 1 mg; serine, quantity: 50 mg; choline bitartrate, quantity: 300 mg; levomefolate calcium, quantity: 542 microgram (equivalent: levomefolic acid, qty 500 microgram) - tablet, film coated - excipient ingredients: potable water; microcrystalline cellulose; povidone; purified water; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; silicon dioxide; magnesium stearate; carnauba wax; hypromellose; macrogol 400; crospovidone - maintain/support energy levels ; maintain/support energy production ; aid/assist healthy red blood cell production ; helps maintain/support haemoglobin formation/synthesis ; helps decrease/reduce homocysteine levels ; aid/assist/helps synthesis of neurotransmitters ; maintain/support nervous system function ; maintains/support healthy foetal development

CHOLINE C 11- choline c11 injection United States - English - NLM (National Library of Medicine)

choline c 11- choline c11 injection

global isotopes, llc d/b/a zevacor molecular - choline c-11 (unii: m4as4xgd4q) (choline c-11 - unii:m4as4xgd4q) - choline c-11 4 mci in 1 ml - choline c11 injection is indicated for positron emission tomography (pet) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (ct) or magnetic resonance imaging (mri). in these patients, 11 c-choline pet imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. suspected prostate recurrence is based upon elevated blood prostate specific antigen (psa) levels following initial therapy. in clinical studies, images were produced with pet/ct coregistration. limitation of use : 11 c-choline pet imaging is not a replacement for histologic verification of recurrent prostate cancer. none. there are no adequate and well controlled studies with choline c11 injection in pregnant women and the fetal radiation dose from a 11 c-choline pet imaging study is unknown. it is not known whether choline c11 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capa

CHOLINE C 11- choline c-11 injection United States - English - NLM (National Library of Medicine)

choline c 11- choline c-11 injection

washington university school of medicine - choline c-11 (unii: m4as4xgd4q) (choline c-11 - unii:m4as4xgd4q) - choline c-11 33.1 mci in 1 ml - choline c 11 injection is indicated for positron emission tomography (pet) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (ct) or magnetic resonance imaging (mri). in these patients, 11 c-choline pet imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. suspected prostate recurrence is based upon elevated blood prostate specific antigen (psa) levels following initial therapy. in clinical studies, images were produced with pet/ct coregistration. limitation of u se: 11 c-choline pet imaging is not a replacement for histologic verification of recurrent prostate cancer. none. pregnancy category c. there are no adequate and well controlled studies with choline c 11 injection in pregnant women and the fetal radiation dose from a 11 c-choline pet imaging study is unknown.  it is not known whether choline c 11 injection can cause f

CHOLINE C 11- choline c-11 injection United States - English - NLM (National Library of Medicine)

choline c 11- choline c-11 injection

mayo clinic - choline c-11 (unii: m4as4xgd4q) (choline c-11 - unii:m4as4xgd4q) - choline c-11 33.1 mci in 1 ml - choline c 11 injection is indicated for positron emission tomography (pet) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (ct) or magnetic resonance imaging (mri). in these patients, 11 c-choline pet imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. suspected prostate recurrence is based upon elevated blood prostate specific antigen (psa) levels following initial therapy. in clinical studies, images were produced with pet/ct coregistration. limitation of u se:   11 c-choline pet imaging is not a replacement for histologic verification of recurrent prostate cancer. none. pregnancy category c. there are no adequate and well controlled studies with choline c 11 injection in pregnant women and the fetal radiation dose from a 11 c-choline pet imaging study is unknown.  it is not known whether choline c 11 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. animal reproduction studies have not been conducted with 11 c-choline. all radiopharmaceuticals, including choline c 11 injection, have a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development and the magnitude of the radiopharmaceutical dose. assess pregnancy status before administering choline c 11 injection to a female of child bearing potential. choline c 11 injection should be given to a pregnant woman only if clearly needed. choline c 11 injection is not indicated for use in women. it is not known whether choline c 11 injection is excreted in human milk.  because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from choline c 11 injection, nursing mothers should use alternative infant nutrition sources (e.g., stored breast milk or infant formula) and pump and discard breast milk for 8 hours (>10 half lives of radioactive decay for 11 c isotope) after administration of the drug or avoid use of the drug, taking into account the importance of the drug to the mother. the safety and effectiveness of choline c 11 injection have not been established in pediatric patients.

CHOLINE C 11- choline c-11 injection United States - English - NLM (National Library of Medicine)

choline c 11- choline c-11 injection

ucsf radiopharmaceutical facility - choline c-11 (unii: m4as4xgd4q) (choline c-11 - unii:m4as4xgd4q) - choline c-11 33.1 mci in 1 ml - choline c 11 injection is indicated for positron emission tomography (pet) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (ct) or magnetic resonance imaging (mri). in these patients, 11 c-choline pet imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. suspected prostate recurrence is based upon elevated blood prostate specific antigen (psa) levels following initial therapy. in clinical studies, images were produced with pet/ct coregistration. limitation of u se: 11 c-choline pet imaging is not a replacement for histologic verification of recurrent prostate cancer. none. pregnancy category c. there are no adequate and well controlled studies with choline c 11 injection in pregnant women and the fetal radiation dose from a 11 c-choline pet imaging study is unknown.  it is not known whether choline c 11 injection can cause fetal harm when administered to a pregnant w

PROVOCHOLINE- methacholine chloride powder, for solution
PROVOCHOLINE INHALATION SOLUTION- methacholine chloride inhalation sol United States - English - NLM (National Library of Medicine)

provocholine- methacholine chloride powder, for solution provocholine inhalation solution- methacholine chloride inhalation sol

methapharm inc. - methacholine chloride (unii: 0w5etf9m2k) (methacholine - unii:03v657zd3v) - methacholine 100 mg in 100 mg - provocholine, used in a methacholine challenge test, is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients five years of age and older who do not have clinically apparent asthma. provocholine is contraindicated in the following: - hypersensitivity to methacholine or other parasympathomimetic agents. reactions have included rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. - baseline fev1 < 60% predicted (adults or pediatric patients) or <1.5 l (adults) risk summary the available data from published literature on provocholine use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies evaluating effects of methacholine chloride on embryofetal development have not been conducted. diagnosis of bronchial airway hyperreactivity with bronchoprovocation challenge is not recommended for pregnant wo

SUCCINYLCHOLINE CHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

succinylcholine chloride injection, solution

hf acquisition co llc, dba healthfirst - succinylcholine chloride (unii: i9l0ddd30i) (succinylcholine - unii:j2r869a8yf) - succinylcholine chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies and known hypersensitivity to the drug. it is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest (see warnings). the risk of hyperkalemia in these patients increases over time and usually peaks at 7 to 10 days after the injury. the risk is dependent on the extent and location of the injury. the precise time of onset and the duration of the risk period are not known.

SUCCINYLCHOLINE CHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

succinylcholine chloride injection, solution

hf acquisition co llc, dba healthfirst - succinylcholine chloride (unii: i9l0ddd30i) (succinylcholine - unii:j2r869a8yf) - succinylcholine chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies and known hypersensitivity to the drug. it is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest (see warnings). the risk of hyperkalemia in these patients increases over time and usually peaks at 7 to 10 days after the injury. the risk is dependent on the extent and location of the injury. the precise time of onset and the duration of the risk period are not known.

SUCCINYLCHOLINE CHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

succinylcholine chloride injection, solution

hf acquisition co llc, dba healthfirst - succinylcholine chloride (unii: i9l0ddd30i) (succinylcholine - unii:j2r869a8yf) - succinylcholine chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies and known hypersensitivity to the drug. it is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest (see warnings). the risk of hyperkalemia in these patients increases over time and usually peaks at 7 to 10 days after the injury. the risk is dependent on the extent and location of the injury. the precise time of onset and the duration of the risk period are not known.

CHOLINE MAGNESIUM TRISALICYLATE liquid United States - English - NLM (National Library of Medicine)

choline magnesium trisalicylate liquid

lannett company, inc. - choline magnesium trisalicylate (unii: djj95fjp1h) (salicylic acid - unii:o414pz4lpz) - salicylic acid 500 mg in 5 ml - osteoarthritis, rheumatoid arthritis and acute painful shoulder : salicylates are considered the base therapy of choice in the arthritides; and choline magnesium trisalicylate preparation is indicated for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and other arthritides. choline magnesium trisalicylate liquid is indicated in the long-term management of these diseases and especially in the acute flare of rheumatoid arthritis. choline magnesium trisalicylate liquid is also indicated for the treatment of acute painful shoulder. choline magnesium trisalicylate liquid is effective and generally well tolerated, and is logical choice whenever salicylate treatment is indicated. it is particularly suitable when a once-a-day or b.i.d. dosage regimen is important to patient compliance; when gastrointestinal intolerance to aspirin is encountered; when gastrointestinal microbleeding or hematologic effects of aspirin are considered a patient hazard; and when interference (or the risk of int